Latest
AI Affairs, home

Tuesday 17 November 2026

Markets · Brief

Isomorphic Labs raises $5 billion in round led by Greenoaks and Sequoia

The Series C follows a $2.1 billion Series B, with the drug developer saying it will put the new capital towards its models, candidate pipeline and clinical infrastructure.

Demis Hassabis stands onstage holding a glass and papers before an audience.
Photo: Jay Dixit, CC BY-SA 4.0, via Wikimedia Commons (cropped)

Isomorphic Labs said on 17 November that it had raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital, following an earlier $2.1 billion Series B. The London-based company designs drug candidates using AI simulation models.

Isomorphic Labs described the round as oversubscribed. It said Andreessen Horowitz and other new investors joined, alongside further investment from Alphabet and participation by existing backers Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. An earlier AI Affairs report described funding talks at a valuation of at least $40 billion.

The company says its IsoDDE drug design engine combines simulation models for work across multiple therapeutic areas and drug types. It reported positive preclinical results in internal oncology and immunology programmes and work with partners. Isomorphic Labs said the proceeds would support further model development, its drug candidate pipeline and infrastructure for clinical development.

The funding in this story is listed in our AI funding tracker.

Sources

Topics: Funding, Healthcare

What should we cover? Tell us

The weekly briefing

The AI Affairs weekly briefing: the week's 10 most important AI stories in business, government and markets, every Monday. We'll email you a link to confirm. Every email has a one-click unsubscribe. Privacy policy